Palisade Bio (Nasdaq: PALI) to Present at the Biocom Global Life Science Partnering Conference
18 févr. 2022 08h30 HE
|
Palisade Bio, Inc.
CARLSBAD, Calif., Feb. 18, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI)...
Palisade Bio (Nasdaq: PALI) to Announce Adhesions Clinical Data at SAGES 2022 Annual Meeting
08 févr. 2022 08h00 HE
|
Palisade Bio, Inc.
CARLSBAD, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI)...
Palisade Bio Granted New U.S. Patent Covering Protease Inhibitor LB1148 for Treating Adhesions and Postoperative Ileus
08 déc. 2021 08h00 HE
|
Palisade Bio, Inc.
Issuance of Additional U.S. Patent No11,202,768 Further Bolsters Palisade Bio’s Patent Portfolio The Company Continues to Advance LB1148 for Key Indications After LB1148 Topline Efficacy Results from...
Palisade Bio Announces the European Patent Office to Grant a Patent for its Lead Drug Candidate LB1148, Providing Protection Through 2035
30 nov. 2021 08h00 HE
|
Palisade Bio, Inc.
CARLSBAD, Calif., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ: PALI), a late-stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI)...
Palisade Bio and Newsoara Announce Positive Topline Efficacy Results from Phase 2 Study of LB1148 Demonstrating Accelerated Return of Bowel Function After Gastrointestinal Surgery
29 juil. 2021 08h15 HE
|
Palisade Bio, Inc.
Statistically significant 1.1-day acceleration in return of bowel function Favorable overall safety profile in 120 patients CARLSBAD, Calif. and SHANGHAI, China, July 29, 2021 (GLOBE NEWSWIRE) --...
Palisade Bio Launches Clinical Steering Committee to Provide Clinical Oversight and Guide Preparation for Late-Stage Clinical Trials of LB1148 in Accelerating Postoperative Return of Bowel Function and Reduction of Post-Surgical Adhesions
15 juin 2021 08h15 HE
|
Palisade Bio, Inc.
CARLSBAD, Calif., June 15, 2021 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) a late-stage biopharma company advancing therapies for acute and chronic gastrointestinal (GI) complications,...
Leading BioSciences Announces Positive Topline Data from Open-Label Gastrointestinal Surgery Study
08 janv. 2021 08h30 HE
|
Leading BioSciences
CARLSBAD, Calif., Jan. 08, 2021 (GLOBE NEWSWIRE) -- Leading BioSciences, Inc. (“LBS”), a privately held company that recently entered into a definitive agreement for a reverse merger with Seneca...